Of note, BCL-2 inhibition via therapeutics like the BCL-2 inhibitor Venetoclax sensitizes cancer cells to apoptosis and has become indispensable for oncological treatment in Chronic Lymphocytic Leukemia (CLL) or Acute Myeloid Leukemia (AML) [14,15,16,17]. The gene discussed is BCL2; the disease is cancer.